Cantor Fitzgerald Reiterates Bullish View on Corbus Pharmaceuticals (CRBP) on Resunab Success

November 14, 2016 7:36 AM EST
Get Alerts CRBP Hot Sheet
Price: $6.58 -4.64%

Rating Summary:
    0 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade CRBP Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating and $17 price target on Corbus Pharmaceuticals (NASDAQ: CRBP) after Resunab achieves median CRISS score of 33% versus placebo 0% at 16 weeks, demonstrating clinical activity in target Scleroderma patients (p = 0.044).

Piros commented, "This morning, Corbus announced positive top-line results from its Phase 2 study with Resunab in patients suffering from diffuse cutaneous systemic sclerosis. In the three month, 42-patient study, Resunab achieved a median CRISS score (the primary endpoint of the study) at 16 weeks (4 weeks of follow-up, following 12-weeks of dosing) of 33% compared with a CRISS score of 0% in placebo treated patients. Furthermore, this separation occurred gradually over the 16 weeks of observation. We view these data as positive, which are in-line with our expectations outlined from our previous report."

For an analyst ratings summary and ratings history on Corbus Pharmaceuticals click here. For more ratings news on Corbus Pharmaceuticals click here.

Shares of Corbus Pharmaceuticals closed at $5.85 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Cantor Fitzgerald

Add Your Comment